HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Pfizer's decision is based on the totality of clinical data
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Subscribe To Our Newsletter & Stay Updated
